1,546 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by IronOak Wealth LLC.

IronOak Wealth LLC. bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,546 shares of the pharmaceutical company's stock, valued at approximately $623,000.

A number of other institutional investors have also added to or reduced their stakes in VRTX. Norges Bank bought a new position in Vertex Pharmaceuticals in the fourth quarter valued at $1,374,948,000. Parnassus Investments LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $731,283,000. Capital World Investors grew its stake in shares of Vertex Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock valued at $11,406,667,000 after buying an additional 1,514,993 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Vertex Pharmaceuticals by 15.8% during the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after buying an additional 1,426,746 shares during the last quarter. Finally, Edgewood Management LLC grew its stake in shares of Vertex Pharmaceuticals by 91.2% during the fourth quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company's stock valued at $1,190,626,000 after buying an additional 1,410,238 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Insider Activity

In other news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VRTX. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. BMO Capital Markets set a $545.00 price objective on Vertex Pharmaceuticals in a research note on Friday, January 31st. Leerink Partnrs cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company cut Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective on the stock. in a research note on Thursday, January 30th. Fourteen investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $515.04.

Vertex Pharmaceuticals Stock Up 0.4%

Vertex Pharmaceuticals stock traded up $1.99 during trading hours on Thursday, hitting $447.09. 882,371 shares of the stock traded hands, compared to its average volume of 1,418,078. The firm's 50-day moving average price is $470.99 and its two-hundred day moving average price is $461.47. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company has a market cap of $114.81 billion, a PE ratio of -203.22, a PEG ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the previous year, the firm posted $4.76 earnings per share. The business's revenue was up 2.6% compared to the same quarter last year. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.